APS Aptose Biosciences Inc
- 0.500
- +0.010+2.04%
Aptose Biosciences Inc News
Aptose Biosciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $7 Price Target
Canadian Investment Banking Group: Maintaining the Aptose Biosciences (APTO.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $6.00.
Aptose Biosciences Analyst Ratings
Buy Rating for Aptose Biosciences on Tuspetinib's Promising AML Study and Synergistic Potential
Aptose Biosciences Analyst Ratings
Piper Sandler Maintains Overweight on Aptose Biosciences, Maintains $5 Price Target
Aptose Biosciences' Strategic Shift to Front-Line AML Therapy Garners Buy Rating
Aptose Biosciences Analyst Ratings
Aptose Biosciences Analyst Ratings
Piper Sandler Sticks to Its Buy Rating for Aptose Biosciences (APTO)
RBC Capital Maintains Outperform on Aptose Biosciences, Lowers Price Target to $18
Aptose Biosciences Analyst Ratings
Buy Rating for Aptose Biosciences: Tuspetinib's Promising Future and Differentiation in FLT3 Inhibition
Aptose Biosciences (APTO) Gets a Buy From Piper Sandler
RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk
Promising Financial Performance and Clinical Developments Bolster Aptose Biosciences' Buy Rating: An Analysis by Joseph Pantginis
Oppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)
Promising Trial Data and Expansion Plans Boost Confidence in Aptose Biosciences: An Analysis of John Newman's Buy Rating
Joseph Pantginis Gives Buy Rating to Aptose Biosciences: Promising Clinical Trials and Strong Safety Profile Drive Recommendation
No Data